Compounded GLP-1 Safety: Key Questions Before You Start

The Titrra Editorial Team··8 min read
A person sitting calmly at a sunlit table, journaling and reviewing notes with a cup of tea, reflecting a thoughtful approach to wellness decisions.

Compounded GLP-1 Safety: Key Questions Before You Start

If you have searched for semaglutide or tirzepatide online, you have probably come across compounding pharmacies offering these medications, sometimes at a lower price or with faster availability than brand-name versions. With supply constraints affecting Ozempic, Wegovy, Mounjaro, and Zepbound over the past couple of years, it makes sense that people have looked for alternatives. If you are in that position, there are some important questions worth sitting with before you decide anything.

This article will not tell you compounded GLP-1s are safe or unsafe for you personally. That is a conversation for you and a licensed clinician. What it can do is lay out the questions that regulators, prescribers, and informed patients are asking right now.

What does "compounded" actually mean?

Compounding pharmacies create customized medications, often by combining or altering ingredients, when a commercially manufactured product does not meet a specific patient need. This practice has a long, legitimate history in medicine. But compounded GLP-1 products are a different situation: they are typically made as copies of brand-name drugs, not as individualized formulations for a documented medical need like an allergy.

This distinction matters because compounded copies do not go through the same regulatory approval process as the branded medications. Brand-name semaglutide and tirzepatide have been evaluated by agencies like the MHRA and reviewed through NICE technology appraisals before reaching patients, with specific dosing, manufacturing, and safety data behind them. Compounded versions have not gone through that same evidentiary path.

Is compounded semaglutide safety different from brand-name?

This is one of the most common questions people ask, and it is a fair one. The honest answer is that safety data on compounded GLP-1 products specifically is limited compared to the extensive clinical trial and post-market surveillance data behind approved semaglutide and tirzepatide.

The MHRA's guidance on GLP-1 medicines has repeatedly warned the public about illegal and unregulated online weight-loss medicines, including an alert ahead of the New Year period urging people to avoid sourcing these drugs outside legitimate, regulated channels. The agency has also issued strengthened warnings about acute pancreatitis, including necrotising and fatal cases, across the GLP-1 and dual GLP-1/GIP class. That warning applies to the drug class generally, but it underscores why sourcing matters: when a product's exact formulation and purity are uncertain, it becomes harder to attribute side effects accurately or trust that dosing is consistent from batch to batch.

Is compounded tirzepatide safe, or does it carry extra risk?

Tirzepatide is newer to the market than semaglutide, and NICE's technology appraisal for tirzepatide in weight management was only published in December 2024. Because the approved formulation is relatively recent, there is even less of a track record for anyone to point to when evaluating compounded versions. The same general principle applies: compounded tirzepatide has not undergone the review process that brand-name Mounjaro or Zepbound products have.

If you are weighing this option, questions worth bringing to a licensed prescriber include:

  • Is the compounding pharmacy registered and licensed in your jurisdiction?
  • What is the source of the active pharmaceutical ingredient?
  • Has the pharmacy provided any third-party testing or purity documentation?
  • Does your prescriber have visibility into what you are actually injecting?

Compounded GLP-1 vs brand-name: what's actually different

The active molecule's mechanism, mimicking the GLP-1 hormone to slow digestion and reduce appetite, is the same in theory. But several things can differ in practice:

  • Manufacturing oversight. Brand-name products are made in facilities subject to regular regulatory inspection. Compounding pharmacies operate under a different regulatory framework.
  • Dose consistency. Approved pens and vials are manufactured to tight concentration tolerances. Compounded products may have more variability batch to batch.
  • Formulation additives. Some compounded versions use salt forms (like semaglutide sodium or acetate) that differ from the approved base compound, with unclear comparative absorption data.
  • Labeling and dosing guidance. Brand products come with extensively tested dosing schedules. Compounded products may not have the same level of guidance behind their instructions.

None of this means every compounded product is unsafe, but it does mean the burden of verification shifts more heavily onto you and your prescriber when the usual regulatory safety net is not fully in place.

Compounding pharmacy GLP-1 risks worth understanding

Beyond the ingredient and dosing questions, there are a few broader risk categories to be aware of:

  • Inconsistent potency. Without standardized manufacturing controls, two vials from the same pharmacy could theoretically differ in strength.
  • Contamination risk. Any compounded sterile injectable carries some risk of contamination if manufacturing conditions are not tightly controlled.
  • Unclear long-term data. Because compounded versions are not the subject of large clinical trials, there is little way to track long-term outcomes specific to them.
  • Monitoring gaps. If you are not working with a clinician who knows you are using a compounded product, routine monitoring like eye exams or liver function checks may not account for it appropriately. If you are already tracking related health markers, resources like GLP-1 and Eye Appointments: Diabetic Retinopathy Screening Guide and GLP-1 Medications and Fatty Liver: What NAFLD Monitoring Shows are useful regardless of which product you use, but they are even more important when your care team has full visibility into your treatment.

If supply issues are the reason you're considering it

Many people turn to compounded options because of real shortages, not because brand-name products aren't working for them. If that is your situation, it may help to look at structured contingency planning first. Our guide on GLP-1 Shortage? Your Backup Plan for Ozempic, Mounjaro, Wegovy walks through options to discuss with a prescriber when your regular medication is unavailable, including communicating with your pharmacy network and understanding substitution guidance.

Questions to bring to your prescriber

Rather than deciding alone, consider bringing these points into a conversation with a licensed clinician:

  • Is a compounded product from a verified, licensed source being recommended or reviewed by you specifically, or is it a general suggestion?
  • How would we monitor for side effects differently, if at all?
  • What would switching back to a brand-name product look like if I start on a compounded version? Our piece on How to Switch Your GLP-1 Injection Day to a Weekend shows how to think through dosing-schedule changes generally, which can be a useful framework if you ever transition between products.
  • What documentation does the compounding pharmacy provide about sourcing and testing?

A tracking companion, not a decision-maker

Whatever path you and your clinician land on, keeping a clear record of your doses, side effects, and any changes in how you feel can help you and your care team make sense of your experience over time. This is especially useful if you ever switch between brand-name and compounded products, since noticing differences in tolerability or appetite response is easier when you have a consistent log.

Titrra is built to help you track that kind of information without judgment. Whether you are navigating supply shortages, considering a switch, or just want a clearer picture of your week-to-week experience, having the data at hand makes conversations with your prescriber more productive.

The bottom line

Compounded GLP-1 medications exist in a different regulatory space than brand-name semaglutide and tirzepatide. Regulators like the MHRA have actively warned the public about unregulated online sources of weight-loss medicines, and the extensive safety review that approved products undergo through bodies like NICE simply has not happened for compounded copies in the same way. That does not mean every compounded product is dangerous, but it does mean the questions above deserve real answers before you start, ideally in partnership with a licensed clinician who knows your full health picture.